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1ABSTRACT
Identification and characterization of preexisting resistant subclone 
in lung cancer with EGFR mutation sensitive to EGFR tyrosine kinase 
inhibitor
Youngjoo Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Joon Chang)
EGFR tyrosine kinase inhibitor (EGFR-TKI) is the first molecularly 
targeted drug to change the paradigm in the management of lung cancer. 
These drugs are specifically effective in lung cancers with activating 
EGFR mutations. However, most cancer that initially responds to 
EGFR-TKI eventually acquires drug resistance. Several mechanisms are 
responsible for acquired resistance to EGFR-TKI, and the most common 
is the emergence of the T790M mutation in EGFR. This study aimed to 
evaluate whether the tumor cells carrying the T790M mutation exists
before drug exposure and expands under the selective drug pressure. We 
collected pretreatment tumor tissues from 124 advanced non-small cell 
lung cancer patients with activating EGFR mutations that were detected 
by direct sequencing. Genotyping for T790M by matrix-assisted laser 
desorption/ionization-time of flight/mass spectrometry identified 31 
(25.0%) tumors with pretreatment T790M. Furthermore, 68 cases which 
additionally underwent droplet digital PCR showed 27 (39.7%) tumors 
had pretreatment T790M mutation. We also observed clonal expansion 
of preexisting T790M clones during EGFR-TKI treatment both in in 
vivo model and in the paired tissue samples. In co-culture study mixing 
2drug-sensitive cell and luciferase-tagging drug-resistant cell, we showed 
this growth advantage of resistant cell in regressing tumors was caused 
by dying sensitive cells. The T790M mutation frequency at which the 
risk of progression to EGFR-TKI begins to increase was estimated to be 
3.2%. The patients with T790M-positive tumor had shorter time to 
progression (TTP) after EGFR-TKI (median 6.3 months vs. 11.5 
months; P < 0.001) and overall survival (OS) (median 16.1 months vs. 
26.5 months; P = 0.065) than those with T790M-negative tumor. 
Among the T790M-positive patients, the patients with high T790M 
frequency (n= 9) had shorter TTP (median 2.4 months vs. 6.7 months; P 
= 0.009) and OS (median 9.1 months vs. 18.7 months; P = 0.018) than 
those with low T790M frequency (n= 22). In conclusions, EGFR 
T790M mutation preexisted substantially in EGFR-mutant lung cancer. 
The T790M clones may expand during EGFR-TKI treatment by dying 
sensitive cell and finally be responsible for the patients’ resistance and 
progression. Thus, the patients with high T790M mutation frequency 
had worse clinical outcomes to EGFR-TKI.
----------------------------------------------------------------------------------------
Keywords: Lung cancer, targeted therapy, EGFR, tyrosine kinase 
inhibitor, acquired resistance, EGFR T790M 
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I. INTRODUCTION
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
(TKI) have shown dramatic response in patients with non-small cell lung 
cancer (NSCLC) harboring sensitizing EGFR mutations.1 However, the 
majority of the patients with EGFR-mutant lung cancer who initially 
respond to EGFR-TKI therapy eventually acquire resistance to the drug 
and experience disease progression. The T790M gatekeeper mutation in 
the EGFR gene is regarded as the most common cause of acquired 
resistance to EGFR-TKI.2, 3 This mutation causes substitution of 
threonine to methionine at codon 790 in the catalytic domain of EGFR. 
This substitution increases the receptor’s affinity for adenosine 
triphosphate and impairs receptor-drug binding by inhibiting hydrogen 
bond formation or inducing steric hindrance.2, 4 This T790M resistant 
4mutation was found in approximately 60% of rebiopsy samples obtained 
from patients with acquired resistance to EGFR-TKI therapy.5
A subset of patients with sensitive EGFR mutations did not respond 
to EGFR-TKI therapy or their response was shorter than expected.6-8 The 
cause of this reduction in the efficacy of targeted therapy in a molecularly 
defined patient population remains unknown. Recently, some case reports 
and preclinical studies have suggested that the T790M resistance 
mutation may exist before EGFR-TKI exposure and may play a 
fundamental role in the inherent resistance of EGFR-mutant tumors to 
EGFR-TKI therapy.9, 10 Based on these findings, it was assumed that 
some subclones with this resistant mutation are present before starting 
EGFR-TKI therapy, albeit at a low frequency, and selective pressure 
from EGFR-TKI therapy may thus cause the expansion of these latent 
resistant subclones, resulting in the emergence of a resistant phenotype in 
the entire population of cells. 
Several studies have tried to prove the presence of preexisting T790M 
mutation in EGFR-mutant lung cancer using genotyping methods that are 
more sensitive than the commonly used direct sequencing method, which 
is usually unable to detect low-frequency mutations.11-16 However, the 
frequency of preexisting T790M mutations reported in prior studies was 
5controversial. Additionally, there was no data about the proportion of 
these resistant clones within each tumor or the clinical outcomes 
according to the proportion of these clones. Especially, it is unclear 
whether the acquisition of whole-tumor resistance is driven by resistant 
tumor cells that are present at a low frequency before starting therapy. 
Thus, we try to identify and characterize latent resistant subclone with 
T790M mutation in lung cancer with EGFR mutation sensitive to EGFR 
tyrosine kinase inhibitor. 
6II. MATERIALS AND METHODS
Patients and tumor samples
Advanced NSCLC patients who underwent routine direct sequencing of 
the EGFR gene and who were treated with an EGFR-TKI (e.g., gefitinib 
or erlotinib) at the National Cancer Center Hospital (Goyang, Republic of 
Korea) between January 2009 and August 2014 were screened for this 
study (Figure 1). Archival formalin-fixed, paraffin-embedded pre-
treatment or posttreatment tumor tissues were collected for genetic 
analysis. A pathologist (K.G.L) reviewed hematoxylin-eosin stained 
sections of each tissue sample and identified tissue areas containing 
≥70% tumor for dissection. Genomic DNA was extracted from the 
dissected tumor tissue using a DNeasy Tissue kit (Qiagen, Valencia, CA, 
USA), according to the manufacturer’s instructions.
7Figure 1. Patient selection and tissue collection.
8Direct sequencing analysis 
Polymerase chain reaction (PCR) amplification was performed with 5 µl 
of the extracted genomic DNA, 1 U of Taq DNA polymerase, 0.25 mM 
each dNTP, 10 mM Tris-HCl, 40 mM KCl, 1.5 mM MgCl2, and 20 pmol 
of the primers in a final volume of 20 µl. The following primers were 
used to amplify exon 20 of EGFR: 5¢-CCATGAGTACGTATTTTG-
AAACTC-3¢ (forward) and 5¢-CATATCCCCATGGCAAACTCTTGC-3¢
(reverse). The PCR cycling parameters were 95 °C for 5 min, 40 cycles at 
95 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s, followed by a final step 
at 72 °C for 10 min. After the PCR products were purified, they were 
directly sequenced with the MegaBACE DNA Analysis System
(Amersham Biosciences, Sunnyvale, CA, USA), with a standard 
published protocol. 
Cases harboring the sensitive mutations (exon 19 deletion and exon 
21 L858R) except those with coexisting T790M mutations were further 
genotyped for the T790M mutation in exon 20. In order to more 
sensitively genotype the T790M mutation, two genotyping methods 
including matrix-assisted laser desorption/ ionization-time of flight/MS 
(MALDI-TOF/MS) (Sequenom, San Diego, CA) and droplet digital 
polymerase chain reaction (ddPCR) (Bio-Rad, Hercules, CA, USA) were 
9used. 
Sensitivity analysis of the MS assay
Serial DNA mixtures of mutant (H1975) and wild-type (HCC827) DNA 
were genotyped by the MS assay to determine the detection limit and 
cutoff value for the T790M mutation (Figure 2A, B). The T790M mutant 
signal calls were detectable in the cluster plot and mass spectrum of the 
DNA mixtures with a T790M mutation frequency of ≥2.5%. The mutant 
signal frequency was calculated as follows: mutant signal frequency (%) 
= (mutant peak height) / (mutant peak height + wild-type peak height) × 
100. The calculated mutant signal frequency in the 2.5% T790M DNA 
mixture was 2.95%. Thus, this value was used as the cutoff value for the 
T790M mutation in further analysis. The diluted mutant DNA percentage 
was linearly correlated with the mutant signal frequency (R2 = 0.9878) 
(Figure 2C).
10
Figure 2. Determination of the detection limit for the T790M mutation 
(790C>T, exon 20) by MALDI-TOF/MS using a serial DNA mixture of mutant 
and wild-type DNA. Mutant and wild-type DNA was extracted from H1975 
cells and H827 cells, respectively, and was mixed at the indicated proportions. 
In the mass spectrum (A) and call cluster plot (B), a peak corresponding to the 
T790M mutant can be seen in the diluted mixtures containing ≥2.5% of mutant 
DNA. (C) The diluted mutant DNA percentage was linearly correlated with the 
mutant signal frequency in the genotyping assay. WT: wild-type peak, M: 
mutant peak. 
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Estimating the allele frequency of T790M in cell lines
The allele frequency of EGFR T790M after gefitinib (LC Laboratories, 
Woburn, MA) or cisplatin treatment was measured in two pairs of cell 
line mixtures containing TKI-sensitive cells and TKI-resistant cells with 
the T790M mutation: HCC827/H1975 and PC-9/PC-9GR-T790M20. The 
HCC827, PC-9, and H1975 cell lines were purchased from Korean Cell 
Line Bank (Seoul, Korea), RIKEN BioResource Center Cell Bank 
(Ibaraki, Japan), and American Type Culture Collection (Manassas, VA), 
respectively. TKI-sensitive cells and TKI-resistant cells with the T790M 
mutation were mixed at the indicated proportions and were treated with 
gefitinib or cisplatin for 72 hours. And then the ddPCR was performed 
for measuring of T790M allele frequency.
12
Figure 3.  Schematic summary of two drug treatment methods
Establishment of gefitinib-resistant cell lines
The gefitinib-resistant cell line (PC-9GR) was generated by continuously 
exposing PC-9 cells to increasing concentrations of gefitinib. Starting at a 
concentration of 0.01 μM, the exposure dose was doubled until it reached 
a final concentration of 1.0 μM. We used two different drug treatment 
regimens, intermittent and continuous exposure (Figure 3). Cells in the 
intermittent treatment group (PC-9/GRi) were exposed to gefitinib in 
culture medium for 72 h, washed, and then cultured in gefitinib-free 
medium until their growth rate was similar to that of the parental cells. 
The cells in the continuous treatment group (PC-9/GRc) were 
continuously exposed to gefitinib at a given concentration and the 
medium was not changed to drug-free medium at any time. When the 
13
growth rate of these cells was equal to that of the parental cells, they 
were exposed to increasing concentrations of gefitinib. The drug-resistant 
phenotypes of both groups of cells were confirmed with a cell viability 
assay. And the MS assay was performed for measuring of T790M allele 
frequency.
Luciferase gene transduction into PC9GR-T790M
We used the pLEX system, a lentivector system purchased from Open 
Biosystems (Huntsville, AL). The firefly luciferase gene (Fluc) obtained 
commercially from Promega (Madison, Wisconsin) were cloned into this 
vector. All the lentiviral vectors were packaged into live lentiviral viruses 
in 293T cells following manufacturer’s instructions.
Bioluminescence imaging
For imaging luciferase, we used the IVIS200 instrument from Caliper 
Life Sciences (Hopkinton, MA). For tissue cultured cells, we imaged 
luciferase signal by adding PBS or colorless OptiMEM medium 
(Invitrogen, Carlsbad, CA) with D-luciferin (Caliper Life Sciences, 
Nature Medicine doi:10.1038/nm.2385 iv Hopkinton, MA) at a 
concentration of 0.15 mg/ml. It was important to image the cells at a set 
14
time point (e.g. 10 minutes) after the administration of D-luciferin so that 
signals from different samples were comparable. After images were taken, 
we used manufacturer supplied software to process the images for 
quantitative data.
To monitor growth of luciferase-tagging cells in vitro, 500 luciferase-
tagging PC-9GR-T790M cells were mixed together with 5000 unlabeled 
PC-9 cells, cultured for 5 days, and measured by use of IVIS200.
Growth of luciferase-tagging cells in vivo was followed through 
non-invasive bioluminescence imaging using the IVIS200 instrument 
(Caliper Life Sciences, Hopkinton, MA). Mice to be imaged were 
injected with 150 mg/kg of D-luciferin (obtained from Caliper Life 
Sciences) intraperitoneally in 200µl of PBS and then anesthetized with 
continuous flow of isofluorane. Imaging of the mice was carried out 10 
minutes later.
Monitoring luciferase-tagging tumor cell in mice
The tumor cell mixtures of PC-9 and luciferase-tagging PC-9GR-T790M 
were subcutaneously injected into the nomobese diabetic/ severe 
combined immunodeficient (NOD/SCID) mice. Groups of mice were 
inoculated with each cell line at 5 x 106. Individual tumor volumes were 
15
measured using a digital caliper and about according to the formular V= 
1/2ab2 (a, the long diameter and b, the short diameter of the tumor). 
When tumor volume was more than 100 m3, 5mg/kg of gefitinib was 
administrated via mouth daily for 5 days/week. Tumor growth from 
luciferase-tagging PC-9GR-790M is monitored through the 
quantification of bioluminescence signals emitted from labeled tumor 
cells by use of the IVIS200 instrument following manufacturer’s 
instructions. 
Cell viability assay
The cells were then seeded at a density of 4 × 103 cells/well in 96-well 
plates. After 24 h, the cells were exposed to different concentrations of 
gefitinib and were incubated for 72 h. The cells were then washed with 
phosphate-buffered saline and the cell viability was measured with the 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, 
Madison, WI, USA), according to the manufacturer’s instructions.
Statistical analysis
Differences between pairs of categorical variables were analyzed using 
the c2 test or Fisher's exact test. Time to progression (TTP) was measured 
16
from the first day of starting EGFR-TKI until the identification of disease 
progression (PD). Overall survival (OS) was calculated from the first day 
of starting EGFR-TKI until death or the most recent follow-up. Survival 
time was estimated using the Kaplan–Meier method and was compared 
between groups using the log-rank test. The Cox proportional hazards 
regression model was used for univariate and multivariate survival 
analyses to determine hazards ratios (HR) with 95% confidence intervals 
(CI). Two-sided values of P < 0.05 were considered statistically 
significant.
17
III. RESULTS
Identification of preexisting EGFR T790M mutations in EGFR-mutant 
lung cancer
T790M was analyzed by direct sequencing, MALDI-TOF MS, and 
ddPCR methods in EGFR-TKI-treated patient cohorts with advanced 
NSCLC. In the pretreatment tissue, direct sequencing could not identify 
any patients with T790M, whereas the MS assay detected 31 of 124 
(25.0%). Among them, 68 with adequate DNA amount and quality were 
further examined by the ddPCR assay. The detection sensitivity of 
T790M mutation by the ddPCR assay was higher than that of the MS 
assay (27 of 68, 39.7%) (Figure 4A). We calculated the ratio of the 
number of T790M alleles to that of activating mutant alleles (T/A) to 
show the distribution of latent T790M burden in this study group (Figure 
4B). The mean value of T/A ratio was 0.5% (range, 0.0%-7.3%) with 
1.12 of standard deviation.  
18
Figure 4. (A) The frequency of patients carrying pretreatment EGFR T790M. 
(B) Distribution of intratumoral T790M/Activating mutation allele frequency 
ratio in 27 pretreatment EGFR-mutant lung cancer tumors.
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Clonal expansion of preexisting EGFR T790M clones during 
EGFR-TKI treatment
The T790M/activating mutation allele frequency ratio after gefitinib or 
cytotoxic chemotherapy was calculated in two pairs of cell line mixtures 
containing TKI-sensitive cells and TKI-resistant cells with the T790M 
mutation (HCC827/H1975 and PC-9/PC-9GR-T790M). In Figure 5, 
TKI-resistant cells carrying the T790M mutation (H1975 and PC-9GR-
T790M) were spiked into TKI-sensitive cells (HCC827 and PC-9) at 
various proportions (0%, 1%, 5%, and 25%). We found that gefitinib 
selected significantly better resistant cells compared with control and 
cisplatin treatment groups. 
20
Figure 5. The T790M/activating mutation allele frequency ratio after gefitinib
or cisplatin treatment in the mixture of lung cancer cell lines. (A) HCC827 + 
H1975 (%). (B) PC9 + PC9-GR-T790M (%).The ddPCR assay was done. *P= 0. 
001, **P= 0.005
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To model heterogeneous tumor cell population in vivo, we mixed a small 
percentage of PC-9GR-T790M cells, labelled with luciferase vector, 
together with mostly non-labelled, PC9 cells, and injected the admixture 
(PC9/PC9GR, 98%/2% or 75%/25%) subcutaneously in mice. After the 
tumors were established, we treated the mice with gefitnib and monitored 
the growth of PC-9GR-T790M resistant cells by bioluminescene imaging 
in vivo. Although gefitinib treatment decreased the volume of the tumors, 
the number of admixed resistant cells in regressing tumors increased 
(Figure 6). 
22
Figure 6. Expansion of luciferase-tagging PC-9GR-T790M cells during 
gefitinib treatment in xenograft mouse model. The transplanted cell mixtures 
included (A) low PC-9GR-T790M (2%) and (B) high PC-9GR-T790M (25%).
23
Figure 7. Change in the T790M/activating mutation allele frequency ratio after 
EGFR-TKI or cytotoxic chemotherapy. The ddPCR assay was done. 
We indirectly confirmed these experiment study findings by using the 
patient samples. Using the ddPCR assay, we measured the T/A ratio of 
the T790M in 12 paired tumor tissues, which were sampled before and 
after EGFR-TKI or cytotoxic chemotherapy. As shown in Figure 7, the 
EGFR-TKI treatment group demonstrated that the presence of T790M
before treatment was correlated to the occurrence of T790M after 
treatment and the percentage of posttreatment T790M increased as that of 
pretreatment T790M increased. However, the chemotherapy treatment 
group showed the T790M percentage was almost not changed after 
24
treatment. These results suggested the clonal expansion of preexisting 
latent T790M cell only under EGFR-TKI treatment.   
Growth stimulation from sensitive cell dying under drug treatment
To evaluate whether the growth advantage of resistant cell in regressing 
tumors was caused by dying sensitive cells, we performed in vitro 
experiments including coculture assay and indirect culture assay using 
cell supernatants. Drug-resistant cells (PC-9GR-T790M) tagged with 
luciferase were cultured together with drug-sensitive cell (PC-9) and then 
their luciferase activity was measured. At first, we confirmed the linear 
correlation between measured activity and actual cell numbers (Figure 
8A). Based on the measured luciferase activity, we observed that 
drug-sensitive cell suppressed the proliferation of drug-resistant cell but 
dying drug-sensitive cell under EGFR-TKI promoted the regrowth of 
drug-resistant cell (Figure 8B). 
25
Figure 8. (A) Correlation between measured luciferase activity and cell 
numbers of luciferase-tagging PC-9GR-T790M. (B) Difference in luciferase 
activity of luciferase-tagging PC-9GR-T790M according to conditions of 5- day 
coculture. Drug: gefitinib= 0.01 µM.
26
Figure 9. Difference in cell viability of PC-9GR-T790M in indirect study. PC-9 
and PC-9GR-T790M cells incubated for 72h in three conditioned media and the 
cell viability assay was done in each group.  
We derived conditioned media (CM) from gefitinib-sensitive cells 
cultured in the absence (CM-vehicle) or presence of gefitinib 
(CM-gefitiib). CM-vehicle suppressed the growth of gefitinib-resistant 
cells whereas CM-gefitinib significantly accelerated, as determined by 
cell viability assays and bioluminescene activity measurement (Figure 9). 
Because all biologically active CM was collected before cell death or 
senescence, it is likely that the secretome is actively produced as a result 
of oncogene inhibition. These results demonstrate that EGFR mutant 
cells respond to therapeutic stress under targeted therapy by secreting 
factors that accelerate the growth of drug resistant minority clones.  
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Effects of the T790M mutation on EGFR-TKI efficacy
The response rate (RR) and disease control rate (DCR) were not 
significantly different between patients with T790M-positive mutant 
tumors and T790M-negative mutant tumors (RR: 71.0% vs. 83.9%, P = 
0.115; DCR: 83.9% vs. 92.5%, P = 0.173). However, the median TTP 
was significantly shorter in patients with T790M-positive mutant tumors 
than in patients with T790M-negative mutant tumors (6.3 months vs. 11.5 
months; P < 0.001) (Figure 10A). Multivariate analysis of TTP showed 
that the risk of progression was significantly higher in patients with 
T790M-positive mutant tumors than in patients with T790M-negative 
mutant tumors (HR 2.43, 95% CI 1.55–3.80, P < 0.001). The shorter TTP 
of T790M-positive mutant tumors was also observed at the 1st line 
EGFR-TKI subgroup (6.0 months vs. 10.5 months; HR 2.06, 95% CI, 
0.94–4.48; P = 0.062) and at the second-line EGFR-TKI or later 
subgroup (6.3 months vs. 11.5 months; HR 2.65, 95% CI, 1.53–4.60; P = 
0.001) (Figure 10B,C).
The median OS was shorter in T790M-positive mutant group than in 
T790M-negative mutant group (16.1 months vs. 26.5 months; HR 2.00, 
95% CI, 1.14–3.53; P = 0.065) (Figure 10D). However, there was no 
significant difference in the median survival after the failure of second 
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EGFR-TKI between two groups (7.9 months vs. 14.2 months; HR 1.59, 
95% CI, 0.90-2.78; P = 0.383). These trends remained unchanged 
according to the presence or absence of exposure to chemotherapy drugs 
before EGFR-TKI therapy.
Figure 10. Kaplan–Meier survival curves. (A) TTP of total patients, (B) TTP of 
1st line group, (C) TTP of ≥ 2nd line group, and (D) OS of total patients in 
EGFR wild-type and EGFR-mutant patients divided into two subgroups 
according to the presence of preexisting T790M mutations.
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Dose-dependent effect of the T790M mutation
The optimal cut-off point of T790M mutant signal frequency which gives 
the most significant HR of progression to EGFR-TKI in T790M-positive 
mutant tumors was 45.7%, which corresponded to percentages of cells 
within a tumor of 28.1%, based on the cell-line mixture study. Patients 
with T790M-positive mutant tumors were divided into two subgroups 
according to this cut-off value of T790M mutant signal frequency. There 
was no significant difference in RR and DCR between high (n= 9) and 
low T790M groups (n= 22) (RR: 66.7% vs. 72.7%, P = 1.000; DCR: 
66.7% vs. 90.9%, P = 0.131). However, the median TTP was 
significantly shorter in high T790M patients than in low T790M patients 
(2.4 months vs. 6.7 months; HR 2.91, 95% CI, 1.26–6.75; P = 0.009) 
(Figure 10E). Additionally, the median OS was significantly shorter in 
high T790M patients than in low T790M patients (9.1 months vs. 18.7 
months; HR 6.14, 95% CI, 1.66–22.77; P = 0.018) (Figure 10H). 
However, there was no significant difference in the median post-TKI 
survival between high T790M patients and low T790M patients (7.9 
months vs. 8.4 months; HR 2.08, 95% CI, 0.81-5.33; P = 0.122).
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Figure 10. Kaplan–Meier survival curves (E) TTP of total patients, (F) TTP of 
1st line group, (G) TTP of ≥ 2nd line group, and (H) OS of total patients in 
EGFR wild-type and EGFR-mutant patients group, including T790M-negative 
patients and T790M-postive patients who were divided two subgroups 
according to the T790M mutant signal frequency.
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Estimated frequency of T790M mutant cells for inducing resistance
A total of 124 EGFR-mutant patients were divided into two groups by the 
cutoff level defined as the median value of deciles of the T790M mutant 
signal frequency. The trends in HRs for TTP during EGFR-TKI therapy 
according to the cutoff levels of the T790M signal frequency. The 
minimum cutoff level of the T790M signal at which the risk of 
progression significantly increased during EGFR-TKI therapy was 5.3%, 
which corresponds to 3.2% of the estimated percentage (Figure 11).
Figure 11. Hazard ratios for TTP following EGFR-TKI therapy according to the 
cutoff levels of the T790M mutant signal frequency in 124 EGFR-mutant 
patients. Hazard ratios were calculated using the Cox proportional hazards 
regression model.
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In vitro sensitivity to gefitinib was significantly lower in the cell 
mixtures containing ≥10% of H1975 cells (TKI-resistant cells) compared 
with that of pure H827 cells (TKI-sensitive cells) (Figure 12A,B). 
Additionally, in mixtures of PC9GR-T790M cells and PC9 cells, the 
minimum percentage of PC9GR-T790M cells that started to show a 
reduction in gefitinib sensitivity relative to pure PC9 cells was 5% 
(Figure 12C,D).
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Figure 12. In vitro experiments for estimating the percentage of T790M cells 
with resistance to gefitinib. TKI-sensitive cells (HCC827 and PC9) and 
TKI-resistant cells with the T790M mutation (H1975 and PC9GR-T790M) were 
mixed at the indicated proportions and were treated with gefitinib. (A, B) 
Mixtures of HCC827 and H1975 cells. (C, D) Mixtures of PC9 and 
PC9GR-T790M cells. *P < 0.01 and **P < 0.001 (Mann–Whitney U test).
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IV. DISCUSSION
The current study semi-quantitatively measured preexisting EGFR
T790M mutation using the MS-based genotyping assay and ddPCR and 
evaluated the clinical significance of its level in advanced NSCLC
patients with sensitive EGFR mutations. These results suggest that the 
preexistence of resistant subclones before TKI exposure is not rare in 
tumors harboring TKI-sensitive mutations, but the latent resistant 
subclones are not always detected by direct sequencing methods because 
of their low frequency. Similar findings have been reported for the other 
tumor types, including KRAS wild-type colorectal cancer.21, 22 The latest 
studies that used deep sequencing methods, either 454 pyrosequencing or 
BEAMing, revealed that KRAS mutations mediate acquired resistance to 
anti-EGFR treatment in KRAS wild-type colorectal cancer and that these 
alterations exist as latent subclones within the tumor before starting 
therapy.21, 22
As described above, advances in sequencing technology have 
provided direct evidence for intratumor genetic heterogeneity, suggesting 
the preexistence of infrequent resistant subclones. However, the impact 
of these resistant subclones on clinical outcomes, including response and 
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resistance to therapy, remains to be elucidated. This study revealed that 
The T790M clones may expand during EGFR-TKI treatment by dying 
sensitive cell and finally be responsible for the patients’ resistance and 
progression. Thus, the presence of latent resistant clones was associated 
with reduced survival benefit from molecular targeted therapy. Although 
patients with preexisting T790M mutations responded to EGFR-TKI 
therapy, the duration of response was much shorter than that of patients 
without the T790M mutation. In particular, the clinical outcome of 
EGFR-TKI therapy was worse in high-leveled T790M patients than in 
low-leveled T790M patients. Thus, the clinical outcome of patients with 
EGFR-mutant tumors harboring a high proportion of the T790M 
mutation was as poor as that of patients with wild-type EGFR. These 
results suggest that the negative impact of the T790M mutation on 
EGFR-TKI efficacy may be dependent on the intratumoral proportion of 
the T790M mutation.
In this study, we used two different approaches to determine the 
lowest frequency of the T790M mutations in EGFR-mutant tumor that 
reduces the efficacy of EGFR-TKI therapy. In both sets of cell-line 
mixture experiments, the mixtures containing 5% or 10% of T790M cells 
showed significantly decreased sensitivity to gefitinib compared with the 
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mixture without T790M cells, whereas the mixtures containing less than 
5% or 10% of T790M cells showed no significant differences in 
sensitivity to gefitinib relative to the mixture without T790M cells. In 
clinical settings, the lowest frequency of T790M cells to affect sensitivity 
to EGFR-TKI therapy was estimated to be 3.2%. This discrepancy 
between the clinical and cell-line results may be explained by the 
difference in the composition of tumor DNA content between the tissue 
samples and the cell lines. Although we selected samples in which the 
tumor comprised ≥70% of the sample, the inclusion of non-malignant 
normal cells, such as stromal and inflammatory cells, possibly resulted in 
underestimation of the lowest frequency of the T790M mutation in tissue 
samples unlike in tumor cell lines. It is also possible that different 
numbers of the T790M allele within each tumor cell could have 
contributed to the discrepancy.
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V. CONCLUSION
Several treatments have been developed to overcome the limitations 
of the first-generation EGFR-TKIs in EGFR-mutant lung cancer and 
several T790M-specific TKIs are currently being evaluated in clinical 
trials. Thus, it is important that we understand the clinical significance of 
the T790M mutation as the major cause of resistance to EGFR-TKI. This 
study revealed that the presence of preexisting T790M mutation is not 
rare event and the frequency of the T790M mutation within a tumor has a 
critical impact on the tumor’s biological characteristics and the clinical 
outcomes of EGFR-TKI therapy. The extent of preexisting EGFR T790M 
mutations is a challenging target for future diagnostic and therapeutic 
studies of EGFR-mutant lung cancer.
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ABSTRACT(IN KOREAN)
EGFR 타이로신 키나아제 저해제에 민감한 EGFR 유전자
돌연변이를 가진 폐암에서 잠복 내성 클론의 존재 확인 및
특성 규명
<지도교수 장 준>
연세대학교 대학원 의학과
이영주
EGFR 타이로신 키나아제 저해제는 폐암 치료의 패러다임을
바꾼 최초의 분자 표적 항암 치료제이다. 이 약물은 민감성
EGFR 유전자 돌연변이를 가진 폐암 환자들에서만 특징적으로
효과가 높다. 그러나 초기에 이 약물에 대한 반응이 좋았던
환자들도 결국에는 약물 내성을 보이고 마는데 이 약물 내성의
원인 중에 가장 많은 부분을 차지하는 것이 EGFR 유전자의
T790M 돌연변이이다. 본 연구는 이러한 T790M 돌연변이를
가진 암세포가 약물에 노출되기 이전부터 존재하면서 약물에
노출된 후 그 수가 증가하는 지를 알아보았다. Sanger 시퀀싱
방법으로 민감성 EGFR 돌연변이의 존재가 확인된 진행성
비소세포폐암 환자 124명에서 치료 전 종양 샘플을 모아서
matrix-assisted laser desorption/ ionization-time of flight/ mass 
spectrometry를 통하여 T790M의 유전형을 확인했을 때 31명
(25%)에서 T790M 돌연변이를 확인할 수 있었고 이차 분석을
위하여 종양 샘플이 남아 있는 68명에서 droplet digital PCR 
통하여 다시 확인했을 때 27명 (39.7%) 에서 T790M 돌연변이를
확인할 수 있었다. 본 연구에서는 또한 약물 치료 동안 T790M 
클론의 확장을 In vivo 모델과 치료 전후 환자 샘플을 이용하여
확인할 수 있었다. 약물 민감성 세포와 luciferase가 표지 된
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약물 내성 세포를 함께 배양했을 때 약물 내성 세포는 약물
민감성 세포가 약물에 의하여 죽어갈 때 특히 잘 성장함을
발견하였다. T790M 돌연변이의 종양 내 수가 3.2%를 넘어설 때
이 약물에 대한 효과가 떨어질 위험도가 높아지기 시작하였다. 
T790M 양성 종양을 가진 환자는 T790M 음성 환자보다 짧은
무진행 생존 기간 및 총 생존 기간을 가졌다. 게다가, T790M 
양성 환자 중에 T790M 돌연변이 분포가 높은 환자는 낮은
환자와 비교할 때 짧은 무진행 생존 기간 및 총 생존 기간을
가졌다. 결론적으로, EGFR 양성 폐암 환자에서 T790M 
돌연변이는 상당량 존재하고 이 돌연변이를 가진 암세포는
주위의 T790M 돌연변이가 없는 약물 민감성 세포가 약물로
인해 죽어감에 영향을 받아서 성장이 촉진됨을 확인할 수
있었다. 이로 인해 T790M 돌연변이 분포가 높은 환자는 이
표적 치료제를 사용함에도 불구하고 불량한 예후를 보였다. 
----------------------------------------------------------------------------------------
핵심되는 말: 폐암, 표적 치료, EGFR, 타이로신 키나아제 저해제, 
후천성 내성, EGFR T790M 
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